European Medicines Agency at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
European Medicines Agency takes part in 6 sessions at World Vaccine Congress Europe 2026 in Amsterdam, its home city. Its sessions cover next-generation vaccine technology, trial design and balancing speed with safety in vaccine access. Specific topics include the role of modelling in vaccine trials, needle-free vaccine delivery, off-target effects of vaccines and communication that builds vaccine literacy.
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
European Medicines Agency Amsterdam, Netherlands | |
The European Union's medicines regulator, evaluating and monitoring vaccines and medicines. | Panel Mon Oct 19 12:15 Panel: Chronic Conditions and Off-target Effects of Vaccines Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it. Panel Mon Oct 19 14:15 Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery Why common doubts about needle-free vaccine delivery, such as cost, regulation and patient uptake, may no longer hold up. Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:00 Working Group: Quality Communication for Vaccine Literacy and Uptake Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions. Supply, safety & access Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
Instantly find 20 buyers from European Medicines Agency
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by Terrapinn or the World Vaccine Congress. Submit a correction